文献速递乳腺癌

早期ERBB2阳性乳腺癌肿瘤浸润淋巴细胞与生存结局:ShortHER随机临床试验10年分析

Tumor-Infiltrating Lymphocytes and Survival Outcomes in Early ERBB2-Positive Breast Cancer: 10-Year Analysis of the ShortHER Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2025-01-01

ShortHER多中心随机试验纳入1253例ERBB2阳性早期乳腺癌患者,866例可评估肿瘤浸润淋巴细胞(TILs)。中位随访9年显示,TILs每增加5%与无远处病生存(HR 0.87)和总生存(HR 0.89)改善相关。TILs≥20%者短疗程治疗10年无远处病生存优于长疗程(92.2% vs 87.1%),交互作用P=0.01。

要点

  • TILs每增加5%,无远处病生存HR 0.87(95%CI 0.80-0.95,P=0.001),总生存HR 0.89(95%CI 0.81-0.98,P=0.01)。
  • TILs≥20%患者短疗程10年无远处病生存92.2% vs 长疗程87.1%,交互作用P=0.01。
  • TILs<20%患者长疗程10年无远处病生存88.7% vs 短疗程81.0%。

核心结论

  • 该随访分析首次显示TILs对接受辅助化疗和抗ERBB2治疗的ERBB2阳性早期乳腺癌患者总生存具有独立影响。
  • TILs≥20%且缩短曲妥珠单抗疗程和化疗剂量的患者未暴露于过高的远处复发或死亡风险。

研究设计与样本

  • ShortHER为意大利多中心随机临床试验,2007年12月至2013年10月入组ERBB2阳性乳腺癌患者。
  • 1253例入组患者中866例女性具有可评估TILs,中位年龄56岁(IQR 48-64)。
  • 数据分析时间为2023年2月至2024年8月,中位随访9年。

主要发现

  • TILs每增加5%与无远处病生存改善相关(HR 0.87;95%CI 0.80-0.95;P=0.001)。
  • TILs每增加5%与总生存改善相关(HR 0.89;95%CI 0.81-0.98;P=0.01)。
  • 10年总生存率:TILs≥20%为91.3%,TILs≥30%为93.3%,TILs≥50%为98.1%,均高于相应较低TILs者。
  • TILs<20%者长疗程 vs 短疗程10年无远处病生存88.7% vs 81.0%;TILs≥20%者长疗程 vs 短疗程87.1% vs 92.2%(交互作用P=0.01)。
  • TILs≥20%者长疗程 vs 短疗程10年总生存89.3% vs 93.1%(HR 0.36;95%CI 0.10-1.36);TILs<20%者长疗程 vs 短疗程91.3% vs 86.9%(HR 1.36;95%CI 0.82-2.23;交互作用P=0.06)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: For patients with early ERBB2 (formerly HER2)-positive breast cancer, there is a need to identify biomarkers to guide treatment de-escalation. OBJECTIVE: To evaluate the association of tumor-infiltrating lymphocytes (TILs) with distant disease-free (DDFS) and overall survival (OS) for patients with ERBB2-positive early breast cancer. DESIGN, SETTING, AND PARTICIPANTS: The ShortHER randomized clinical trial was a multicentric trial in Italy that enrolled patients with ERBB2-positive breast cancer from December 2007 to October 2013. Patients received 9 weeks or 1 year of adjuvant trastuzumab combined with chemotherapy. Tumor samples were evaluated for TILs. Herein, patients were evaluated at a median follow-up of 9 years, and data were analyzed from February 2023 to August 2024. INTERVENTION: Four cycles of anthracycline-based chemotherapy followed by 4 courses of taxanes combined with trastuzumab for 1 year (long arm) or 3 courses of taxanes combined with trastuzumab for 9 weeks followed by reduced-dose anthracycline-based chemotherapy for 3 courses (short arm). MAIN OUTCOMES AND MEASURES: The association of TILs with DDFS and OS was assessed with Cox models. RESULTS: Of 1253 patients enrolled in the ShortHER trial, 866 women (median [IQR] age, 56 [48-64] years) had evaluable TILs. In Cox models with relevant factors, each 5% TIL increment was associated with improved DDFS (hazard ratio [HR], 0.87; 95% CI, 0.80-0.95; P = .001) and OS (HR, 0.89; 95% CI, 0.81-0.98; P = .01). The 10-year OS rate was 91.3% for patients with TILs 20% or higher, 93.3% for patients with TILs 30% or higher, and 98.1% for patients with TILs 50% or higher, resulting higher vs lower TIL counterparts. Patients with TILs lower than 20% showed a better outcome with the long vs short treatment (10-year DDFS, 88.7% vs 81.0%), whereas patients with TILs 20% or higher showed the opposite (10-year DDFS, 87.1% vs 92.2%; P for interaction = .01). Similarly, patients with TILs 20% or higher had a 10-year OS rate of 89.3% in the long arm vs 93.1% in the short arm (HR, 0.36; 95% CI, 0.10-1.36); patients with TILs lower than 20% had a 10-year OS rate of 91.3% in the long arm vs 86.9% in the short arm (HR, 1.36; 95% CI, 0.82-2.23; P for interaction = .06). CONCLUSIONS AND RELEVANCE: This follow-up analysis of the ShortHER randomized clinical trial is, to our knowledge, the first demonstration of an independent effect of TILs in terms of OS for patients with ERBB2-positive early breast cancer treated with adjuvant chemotherapy and anti-ERBB2 therapy. Patients with TILs 20% or higher who de-escalated trastuzumab duration and chemotherapy dose were not exposed to an excess risk of distant relapse or death. TRIAL REGISTRATION: EudraCT: 2007-004326-25.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Dieci MV, Bisagni G, Bartolini S, et al. Tumor-Infiltrating Lymphocytes and Survival Outcomes in Early ERBB2-Positive Breast Cancer: 10-Year Analysis of the ShortHER Randomized Clinical Trial. JAMA Oncol. 2025. PMID: 39946142. doi:10.1001/jamaoncol.2024.6872

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。